Form D · Other Technology
Sanguine BioSciences, Inc.
Sherman Oaks, CA · CIK 0001626185
Offering snapshot reported Nov 25, 2014 · SEC filing
- Reported sold
- $5.53M Offering amount: $6.98M
- Investors reported
- 74 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 14, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 25, 2014 | Initial | $5,534,250 | No comparison | 74 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-229065
Source: Form D, filed Nov 25, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rudiger Hausherr | Director |
| Brian Neman | Director, Executive |
| Randy Socol | Executive |
| Tim Triche | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
15335 Morrison Street, Suite 235
Sherman Oaks, CA, 91403
Sherman Oaks, CA, 91403